Blueprint Medicines - BPMC Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $72.68
Forecasted Upside: 61.56%
Number of Analysts: 16
Breakdown:
1 Sell Ratings
6 Hold Ratings
8 Buy Ratings
1 Strong Buy Ratings

^$44.99 As of 03/31/2023 01:00 AM ET

▲ +0.7 (1.58%)

1 month | 3 months | 12 months

Get New Blueprint Medicines Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for BPMC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BPMC

^$72.68

▲ +61.56% Upside Potential

This price target is based on 16 analysts offering 12 month price targets for Blueprint Medicines in the last 3 months. The average price target is $72.68, with a high forecast of $114.00 and a low forecast of $38.00. The average price target represents a 61.56% upside from the last price of $44.99.

Current Consensus is Buy

The current consensus among 16 polled investment analysts is to buy stock in Blueprint Medicines. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

1 strong buy ratings
7 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

10/8/2021

1 strong buy ratings
4 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

1/6/2022

1 strong buy ratings
5 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

4/6/2022

1 strong buy ratings
5 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

7/5/2022

1 strong buy ratings
7 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

10/3/2022

1 strong buy ratings
8 buy ratings
6 hold ratings
1 sell ratings

Ratings as of

1/1/2023

1 strong buy ratings
8 buy ratings
6 hold ratings
1 sell ratings

Ratings as of

3/2/2023

1 strong buy ratings
8 buy ratings
6 hold ratings
1 sell ratings

Ratings as of

4/1/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/30/2023	JMP Securities	Reiterated Rating	Market Outperform	$114.00	Low
3/21/2023	Stifel Nicolaus	Boost Target		$80.00 ➝ $84.00	Low
2/28/2023	JMP Securities	Reiterated Rating	Market Perform	$114.00	Low
2/28/2023	HC Wainwright	Reiterated Rating	Buy	$70.00	Low
2/28/2023	Needham & Company LLC	Reiterated Rating	Buy	$57.00	Low
2/24/2023	SVB Securities	Lower Target		$45.00 ➝ $38.00	Low
2/24/2023	SVB Leerink	Lower Target	Market Perform	$45.00 ➝ $38.00	Low
2/17/2023	Needham & Company LLC	Lower Target	Buy	$60.00 ➝ $57.00	N/A
2/17/2023	HC Wainwright	Reiterated Rating	Buy	$70.00	N/A
2/17/2023	Raymond James	Lower Target	Strong-Buy	$115.00 ➝ $85.00	N/A
2/10/2023	Needham & Company LLC	Reiterated Rating	Buy	$60.00	Low
1/27/2023	Morgan Stanley	Lower Target	Equal Weight	$75.00 ➝ $50.00	Low
1/23/2023	Barclays	Lower Target	Equal Weight	$50.00 ➝ $44.00	Low
1/2/2023	Wells Fargo & Company	Upgrade	Underweight ➝ Equal Weight	$41.00	Low
12/14/2022	Needham & Company LLC	Initiated Coverage	Buy	$60.00	Low
12/12/2022	Barclays	Lower Target	Equal Weight	$58.00 ➝ $53.00	Low
11/4/2022	JMP Securities	Lower Target	Market Outperform	$152.00 ➝ $114.00	Low
11/3/2022	The Goldman Sachs Group	Lower Target	Buy	$143.00 ➝ $108.00	Low
11/2/2022	Jefferies Financial Group	Lower Target		$84.00 ➝ $80.00	Low
11/2/2022	SVB Leerink	Lower Target	Market Perform	$57.00 ➝ $52.00	Low
11/2/2022	Morgan Stanley	Lower Target	Equal Weight	$80.00 ➝ $75.00	Low
11/2/2022	Barclays	Lower Target	Equal Weight	$70.00 ➝ $58.00	Low
11/2/2022	Wedbush	Lower Target	Outperform	$120.00 ➝ $106.00	Low
11/2/2022	HC Wainwright	Lower Target	Buy	$80.00 ➝ $70.00	N/A
11/2/2022	Oppenheimer	Downgrade	Outperform ➝ Market Perform		Low
9/14/2022	Berenberg Bank	Initiated Coverage	Buy	$90.00	Low
9/9/2022	Morgan Stanley	Boost Target	Equal Weight	$65.00 ➝ $80.00	Low
9/7/2022	Credit Suisse Group	Boost Target		$80.00 ➝ $90.00	Low
9/6/2022	Oppenheimer	Boost Target	Outperform	$80.00 ➝ $90.00	Low
8/22/2022	Jefferies Financial Group	Boost Target	Buy	$78.00 ➝ $84.00	Low
8/18/2022	SVB Leerink	Lower Target	Market Perform ➝ Market Perform	$65.00 ➝ $57.00	Low
8/18/2022	Stifel Nicolaus	Boost Target	Buy	$93.00 ➝ $100.00	Low
8/17/2022	HC Wainwright	Lower Target	Buy	$100.00 ➝ $80.00	Low
8/3/2022	Raymond James	Lower Target	Strong-Buy	$133.00 ➝ $115.00	Low
8/3/2022	HC Wainwright	Reiterated Rating	Buy		Low
8/3/2022	The Goldman Sachs Group	Boost Target	Buy	$126.00 ➝ $143.00	Low
8/3/2022	SVB Leerink	Boost Target	Market Perform	$56.00 ➝ $65.00	Low
8/2/2022	Piper Sandler	Lower Target		$65.00 ➝ $59.00	Low
7/7/2022	Oppenheimer	Initiated Coverage	Outperform	$80.00	N/A
7/1/2022	Stifel Nicolaus	Lower Target		$98.00 ➝ $90.00	Low
7/1/2022	SVB Leerink	Lower Target	Market Perform	$60.00 ➝ $56.00	Low
6/27/2022	Wells Fargo & Company	Initiated Coverage	Underweight	$40.00	Low
6/14/2022	Morgan Stanley	Lower Target	Equal Weight	$92.00 ➝ $65.00	Low
6/13/2022	SVB Leerink	Lower Target	Market Perform	$82.00 ➝ $60.00	Low
6/10/2022	HC Wainwright	Reiterated Rating	Buy	$100.00	High
6/9/2022	Citigroup	Downgrade	Neutral ➝ Sell	$68.00 ➝ $41.00	High
6/9/2022	JMP Securities	Reiterated Rating	Buy	$152.00	High
6/1/2022	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$88.00 ➝ $78.00	High
5/18/2022	Piper Sandler	Lower Target	Neutral	$84.00 ➝ $65.00	High
5/4/2022	Robert W. Baird	Lower Target		$123.00 ➝ $96.00	Medium
4/13/2022	Citigroup	Lower Target	Neutral	$71.00 ➝ $68.00	High
4/11/2022	JMP Securities	Reiterated Rating	Buy	$152.00	Medium
3/4/2022	Stifel Nicolaus	Boost Target	Buy	$100.00 ➝ $105.00	Medium
2/28/2022	Wedbush	Reiterated Rating	Outperform	$126.00	Low
2/28/2022	Citigroup	Initiated Coverage	Neutral	$71.00	Low
2/17/2022	SVB Leerink	Lower Target	Outperform ➝ Market Perform	$93.00 ➝ $82.00	High
2/17/2022	HC Wainwright	Lower Target	Buy	$135.00 ➝ $100.00	High
2/1/2022	Morgan Stanley	Lower Target	Equal Weight	$111.00 ➝ $92.00	Medium
1/24/2022	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$120.00 ➝ $95.00	Low
1/12/2022	SVB Leerink	Lower Target	Outperform	$132.00 ➝ $120.00	High
1/3/2022	Guggenheim	Boost Target		$120.00 ➝ $122.00	High
11/30/2021	HC Wainwright	Reiterated Rating	Buy	$134.00	High
11/30/2021	JMP Securities	Reiterated Rating	Buy	$151.00	High
11/10/2021	Raymond James	Boost Target	Strong-Buy	$122.00 ➝ $133.00	Low
10/29/2021	Morgan Stanley	Boost Target	Equal Weight	$96.00 ➝ $111.00	High
7/30/2021	Morgan Stanley	Lower Target	Equal Weight	$101.00 ➝ $96.00	Medium
6/17/2021	Wedbush	Lower Target	Outperform	$136.00 ➝ $130.00	High
6/17/2021	SVB Leerink	Boost Target	Outperform	$127.00 ➝ $137.00	Low
6/17/2021	Robert W. Baird	Boost Target	Outperform	$119.00 ➝ $123.00	High
4/30/2021	Morgan Stanley	Lower Target	Equal Weight	$105.00 ➝ $101.00	High
4/13/2021	Wedbush	Boost Target	Outperform	$119.00 ➝ $136.00	Low
3/30/2021	Credit Suisse Group	Initiated Coverage	Neutral	$100.00	High
2/25/2021	Morgan Stanley	Lower Target	Equal Weight	$112.00 ➝ $105.00	Low
2/18/2021	HC Wainwright	Reiterated Rating	Buy		High
2/18/2021	Barclays	Boost Target	Equal Weight	$90.00 ➝ $95.00	High
1/12/2021	SVB Leerink	Boost Target	Positive ➝ Outperform	$121.00 ➝ $127.00	High
12/18/2020	JMP Securities	Boost Target	Outperform	$118.00 ➝ $152.00	High
12/14/2020	BMO Capital Markets	Boost Target	Outperform	$113.00 ➝ $132.00	Medium
12/2/2020	Stifel Nicolaus	Initiated Coverage	Hold	$110.00	High
11/2/2020	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$90.00 ➝ $96.00	High
11/2/2020	HC Wainwright	Boost Target	Buy	$110.00 ➝ $135.00	High
10/30/2020	Wedbush	Boost Target		$102.00 ➝ $115.00	Low
10/30/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$112.00	Low
10/29/2020	Piper Sandler	Boost Target	Neutral	$77.00 ➝ $81.00	Medium
10/16/2020	Raymond James	Boost Target	Positive ➝ Strong-Buy	$106.00 ➝ $122.00	Medium
10/13/2020	Morgan Stanley	Boost Target	Overweight	$92.00 ➝ $100.00	Low
9/23/2020	SVB Leerink	Boost Target	Outperform	$107.00 ➝ $121.00	Medium
9/23/2020	BMO Capital Markets	Boost Target	Outperform	$105.00 ➝ $113.00	Medium
9/23/2020	Barclays	Boost Target	Equal Weight	$77.00 ➝ $90.00	Medium
9/22/2020	Raymond James	Reiterated Rating	Buy		Medium
9/2/2020	Raymond James	Reiterated Rating	Buy		High
7/31/2020	HC Wainwright	Reiterated Rating	Buy		Low
7/27/2020	SVB Leerink	Boost Target	Outperform	$106.00 ➝ $107.00	Medium
7/15/2020	Morgan Stanley	Boost Target	Overweight	$88.00 ➝ $92.00	Low
7/15/2020	Barclays	Reiterated Rating	Hold ➝ Neutral		High
7/15/2020	Deutsche Bank Aktiengesellschaft	Boost Target	Buy	$85.00 ➝ $95.00	Medium
7/15/2020	SVB Leerink	Boost Target	Outperform	$105.00 ➝ $106.00	High
7/15/2020	HC Wainwright	Boost Target	Buy	$66.00 ➝ $110.00	High
7/14/2020	Robert W. Baird	Boost Target	Outperform	$90.00 ➝ $100.00	High
7/14/2020	Raymond James	Boost Target	Positive ➝ Strong-Buy	$95.00 ➝ $106.00	High
6/8/2020	Deutsche Bank Aktiengesellschaft	Boost Target	Positive ➝ Buy	$70.00 ➝ $85.00	High
6/8/2020	BMO Capital Markets	Boost Target	Outperform	$75.00 ➝ $111.00	High
5/7/2020	HC Wainwright	Reiterated Rating	Buy	$66.00	Medium
5/4/2020	Barclays	Initiated Coverage	Equal Weight	$59.00	Low
4/30/2020	Morgan Stanley	Lower Target	Overweight	$103.00 ➝ $88.00	Low
4/29/2020	JMP Securities	Lower Target	Market Outperform	$107.00 ➝ $103.00	Medium
4/29/2020	BMO Capital Markets	Lower Target	Outperform	$89.00 ➝ $75.00	Medium
4/29/2020	SVB Leerink	Lower Target	Outperform	$125.00 ➝ $105.00	Medium
4/29/2020	HC Wainwright	Lower Target	Buy	$100.00 ➝ $66.00	Medium
3/24/2020	Wedbush	Reiterated Rating	Outperform		High
3/17/2020	SVB Leerink	Boost Target	Outperform ➝ Positive	$116.00 ➝ $125.00	Medium
3/17/2020	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$74.00 ➝ $89.00	High
3/16/2020	Cowen	Initiated Coverage	Buy		High
3/16/2020	Deutsche Bank Aktiengesellschaft	Upgrade	Hold ➝ Buy	$70.00	High
2/18/2020	Morgan Stanley	Lower Target	Overweight	$108.00 ➝ $103.00	Low
2/13/2020	Cowen	Reiterated Rating	Buy		High
1/27/2020	BMO Capital Markets	Initiated Coverage	Market Perform	$74.00	Low
1/15/2020	Wedbush	Reiterated Rating	Positive ➝ Outperform	$141.00 ➝ $122.00	Low
1/10/2020	SVB Leerink	Boost Target		$103.00 ➝ $120.00	Low
1/9/2020	HC Wainwright	Reiterated Rating	Buy		Medium
12/20/2019	Piper Jaffray Companies	Lower Target	Neutral	$85.00 ➝ $77.00	Low
12/10/2019	Deutsche Bank Aktiengesellschaft	Lower Target	Hold	$75.00 ➝ $70.00	Low
12/2/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Sell		Medium
11/7/2019	HC Wainwright	Reiterated Rating	Buy	$100.00	Low
11/6/2019	Raymond James	Upgrade	Outperform ➝ Strong-Buy	$106.00 ➝ $112.00	Medium
10/28/2019	Deutsche Bank Aktiengesellschaft	Downgrade	Buy ➝ Hold	$110.00 ➝ $75.00	High
10/22/2019	JMP Securities	Initiated Coverage	Outperform	$106.00	High
10/11/2019	Morgan Stanley	Lower Target	Overweight	$110.00 ➝ $109.00	Low
10/3/2019	HC Wainwright	Initiated Coverage	Buy	$100.00	High
9/30/2019	Cowen	Reiterated Rating	Buy		High
9/12/2019	Raymond James	Upgrade	Market Perform ➝ Outperform		Low
9/9/2019	Piper Jaffray Companies	Reiterated Rating	Hold		Low
9/9/2019	Cowen	Reiterated Rating	Buy		High
8/29/2019	Piper Jaffray Companies	Initiated Coverage	Neutral	$85.00	Low
8/14/2019	Raymond James	Reiterated Rating	Mkt Perform ➝ Market Perform		High
7/18/2019	Robert W. Baird	Initiated Coverage	Outperform	$120.00	Medium
7/18/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy ➝ Buy	$110.00	Medium
6/17/2019	Cowen	Reiterated Rating	Buy		Low
6/2/2019	Cowen	Reiterated Rating	Buy		High
5/23/2019	The Goldman Sachs Group	Reiterated Rating	Buy ➝ Buy	$125.00	High
4/3/2019	Morgan Stanley	Initiated Coverage	Overweight	$112.00	Low
3/28/2019	Cowen	Reiterated Rating	Buy		High
2/26/2019	Wedbush	Reiterated Rating	Outperform		High
2/26/2019	Cowen	Reiterated Rating	Buy		Medium
1/7/2019	Wedbush	Reiterated Rating	Outperform	$103.00	High
11/15/2018	Cowen	Reiterated Rating	Buy		High
10/22/2018	Wedbush	Reiterated Rating	Outperform	$101.00	Medium
10/8/2018	Wedbush	Reiterated Rating	Outperform	$101.00	Low
10/7/2018	Cowen	Reiterated Rating	Buy		Low
9/25/2018	SVB Leerink	Initiated Coverage	Outperform ➝ Outperform	$105.00	Medium
9/18/2018	Guggenheim	Initiated Coverage	Buy	$102.00	High
8/1/2018	Cowen	Reiterated Rating	Buy		High
6/4/2018	JMP Securities	Lower Target	Market Outperform ➝ Buy	$109.00 ➝ $103.00	High
4/16/2018	Wedbush	Boost Target	Outperform ➝ Outperform	$98.00 ➝ $106.00	High
4/16/2018	JMP Securities	Set Target	Buy	$97.00 ➝ $109.00	High

(Data available from 4/1/2018 forward)

News Sentiment Rating

0.80 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

9 very positive mentions
13 positive mentions
4 negative mentions
2 very negative mentions

Mentions as of

9/3/2022

2 very positive mentions
9 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/3/2022

2 very positive mentions
6 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

11/2/2022

2 very positive mentions
6 positive mentions
3 negative mentions
2 very negative mentions

Mentions as of

12/2/2022

2 very positive mentions
7 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

1/1/2023

6 very positive mentions
11 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/31/2023

12 very positive mentions
18 positive mentions
3 negative mentions
2 very negative mentions

Mentions as of

3/2/2023

9 very positive mentions
7 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/1/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

americanbankingnews.com
8 hours ago
Blueprint Medicines Co. (NASDAQ:BPMC) Receives $71.72 Consensus PT from Brokerages
markets.businessinsider.com
3/30/2023
16 Analysts Have This to Say About Blueprint Medicines
markets.businessinsider.com
3/30/2023
JMP Securities Keeps Their Buy Rating on Blueprint Medicines (BPMC)
finance.yahoo.com
3/28/2023
Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222
marketbeat.com
3/27/2023
Blueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Recommendation of "Hold" by Brokerages

Very Positive

marketbeat.com
3/31/2023
Blueprint Medicines (NASDAQ:BPMC) Stock Rating Reaffirmed by JMP Securities
marketbeat.com
3/30/2023
Assenagon Asset Management S.A. Reduces Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)
seekingalpha.com
3/29/2023
Exploring Blueprint's 'Blockbuster Opportunity' In Indolent Systemic Mastocytosis
marketbeat.com
3/19/2023
Peregrine Capital Management LLC Buys 15,954 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
marketbeat.com
3/13/2023
Ensign Peak Advisors Inc Lowers Stake in Blueprint Medicines Co. (NASDAQ:BPMC)

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Today's Range

Now: $44.99

$44.32

$45.74

50 Day Range

MA: $44.60

$37.97

$49.06

52 Week Range

Now: $44.99

$37.82

$79.40

Volume

470,742 shs

Average Volume

629,597 shs

Market Capitalization

$2.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Blueprint Medicines?: The following Wall Street analysts have issued stock ratings on Blueprint Medicines in the last year: Barclays PLC, Berenberg Bank, Citigroup Inc., Credit Suisse Group AG, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, SVB Securities, The Goldman Sachs Group, Inc., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for BPMC.
What is the current price target for Blueprint Medicines?: 19 Wall Street analysts have set twelve-month price targets for Blueprint Medicines in the last year. Their average twelve-month price target is $72.68, suggesting a possible upside of 61.6%. JMP Securities has the highest price target set, predicting BPMC will reach $114.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $38.00 for Blueprint Medicines in the next year.
View the latest price targets for BPMC.
What is the current consensus analyst rating for Blueprint Medicines?: Blueprint Medicines currently has 1 sell rating, 6 hold ratings, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BPMC will outperform the market and that investors should add to their positions of Blueprint Medicines.
View the latest ratings for BPMC.
What other companies compete with Blueprint Medicines?: Other companies that are similar to Blueprint Medicines include Arrowhead Pharmaceuticals, Axsome Therapeutics, Revance Therapeutics, Ultragenyx Pharmaceutical and Myovant Sciences. Learn More about companies similar to Blueprint Medicines.
How do I contact Blueprint Medicines' investor relations team?: Blueprint Medicines' physical mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company's listed phone number is (617) 374-7580 and its investor relations email address is [email protected] The official website for Blueprint Medicines is www.blueprintmedicines.com. Learn More about contacing Blueprint Medicines investor relations.

Blueprint Medicines - BPMC Stock Price Target and Predictions

Analyst Price Target for BPMC

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.80 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Blueprint Medicines?

What is the current price target for Blueprint Medicines?

What is the current consensus analyst rating for Blueprint Medicines?

What other companies compete with Blueprint Medicines?

How do I contact Blueprint Medicines' investor relations team?